Morbidity, mortality, physiologic and functional parameters in elderly and non-elderly patients in the valsartan heart failure trial (Val-HeFT)

American Heart Journal

Volumn 148, Issue 6, 2004, Pages 951-957

  Baruch, Lawrence ^a   Glazer, Robert D ^b   Aknay, Nora ^b   Vanhaecke, Johan ^c   Thomas Heywood, J ^d   Anand, Inder ^e   Krum, Henry ^f   Hester, Allen ^b   Cohn, Jay N ^g  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

^c UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^d LOMA LINDA UNIVERSITY MEDICAL CENTER   (United States)

^e VA MEDICAL CENTER   (United States)

^f MONASH UNIVERSITY MEDICAL SCHOOL   (Australia)

^g UNIVERSITY OF MINNESOTA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALDOSTERONE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; NORADRENALIN; PLACEBO; SPIRONOLACTONE; VALSARTAN;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIZZINESS; DRUG EFFECT; FEMALE; HEART ATRIUM FIBRILLATION; HEART FAILURE; HORMONAL REGULATION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPOTENSION; KIDNEY DISEASE; MAJOR CLINICAL STUDY; MALE; MEDICAL EXAMINATION; MORBIDITY; MORTALITY; PHYSIOLOGY; PRIORITY JOURNAL; QUALITY OF LIFE; REDUCTION; STATISTICAL ANALYSIS; VERTIGO;

ADULT; AGE FACTORS; AGED; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; DOUBLE-BLIND METHOD; FEMALE; HEART FAILURE, CONGESTIVE; HUMANS; MALE; MIDDLE AGED; NEUROTRANSMITTER AGENTS; QUALITY OF LIFE; TETRAZOLES; TREATMENT OUTCOME; VALINE; VENTRICULAR FUNCTION, LEFT;

EID: 10644255525     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ahj.2004.06.001     Document Type: Article

References (23)

1. Ho K.K., Anderson K.M., Kannel W.B., et al. Survival after the onset of congestive heart failure in Framingham Heart Study subjects. Circulation. 88:1993;107-115
2. McDonagh T.A., Morrison C.E., Lawrence A., et al. Symptomatic and asymptomatic left-ventricular systolic dysfunction in an urban population. Lancet. 350:1997;829-833
3. Kannel W.B., Belanger A.J. Epidemiology of heart failure. Am Heart J. 121:1991;951-957
4. Brown A.M., Cleland J.G. Influence of concomitant disease on patterns of hospitalization in patients with heart failure discharged from Scottish hospitals in 1995. Eur Heart J. 19:1998;1063-1069
5. Cleland J.G., Swedberg K., Poole-Wilson P.A. Successes and failures of current treatment of heart failure. Lancet. 352:(Suppl 1):1998;SI19-SI28
6. Cleland J.G. Heart failure a medical hydra. Lancet. 352:(Suppl 1):1998;SI1-SI2
7. Parameshwar J., Shackell M.M., Richardson A., et al. Prevalence of heart failure in three general practices in northwest London. Br J Gen Pract. 42:1992;287-289
8. Cleland J.G., Gemmell I., Khand A., et al. Is the prognosis of heart failure improving? Eur J Heart Fail. 1:1999;229-241
9. McMurray J., McDonagh T., Morrison C.E., et al. Trends in hospitalization for heart failure in Scotland 1980-1990. Eur Heart J. 14:1993;1158-1162
10. Cleland J.G., Clark A. Has the survival of the heart failure population changed? Lessons from trials. Am J Cardiol. 83:1999;112D-119D
11. Hunt S.A., Baker D.W., Chin M.H., et al. ACC/AHA Guidelines for the evaluation and management of chronic heart failure in the adult executive summary. A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee to Revise the 1995 Guidelines for the Evaluation and Management of Heart Failure): Developed in Collaboration With the International Society for Heart and Lung Transplantation; Endorsed by the Heart Failure Society of America. Circulation. 104:2001;2996-3007
12. Cohn J.N., Tognoni G., Glazer R.D., et al. Rationale and design of the Valsartan Heart Failure Trial a large multinational trial to assess the effects of valsartan, an angiotensin-receptor blocker, on morbidity and mortality in chronic congestive heart failure. J Card Fail. 5:1999;155-160
13. Cohn J.N., Tognoni G. A randomized trial of the angiotensin-receptor blocker valsartan in chronic heart failure. N Engl J Med. 345:2001;1667-1675
14. Latini R., Masson S., Anand I., et al. Effect of valsartan on circulating brain natriuretic peptide and norepinephrine in symptomatic chronic heart failure. Circulation. 106:2002;2454-2458
15. Cohn J.N., Anand I.S., Latini R., et al. Sustained reduction of aldosterone in response to the angiotensin receptor blocker valsartan in patients with chronic heart failure results from Val-HeFT. Circulation. 108:2003;1306-1309
16. Wong M., Staszewsky L., Latini R., et al. Valsartan benefits left ventricular structure and function in heart failure Val-HeFT echocardiographic study. J Am Coll Cardio. 40:2002;970. -5vi
17. Carson P., Tognoni G., Cohn J.N. Effect of valsartan on hospitalization results from Val-HeFT. J Cardiac Fail. 9:2003;164-171
18. Havranek E.P., Abrams F., Stevens E., et al. Determinants of mortality in elderly patients with heart failure the role of angiotensin-converting enzyme inhibitors. Arch Intern Med. 158:1998;2024-2028
19. Ahmed A., Allman R.M., DeLong J.F., et al. Age-related underutilization of angiotensin-converting enzyme inhibitors in older hospitalized heart failure patients. South Med J. 95:2002;703-710
20. Singh V., Christiana J., Frishman W.H. How to use calcium antagonists in hypertension putting the JNC-VI guidelines into practice. Joint National Committee for the Prevention, Detection, Evaluation and Treatment of High Blood Pressure. Drugs. 58:1999;579-587
21. de Leeuw P.W., Birkenhager W.H. The elderly hypertensive; cardiovascular and neurohormonal profile. Cardiovasc Drugs Ther. 15:2001;263-267
22. Seifarth C., Trenkel S., Schobel H., et al. Influence of antihypertensive medication on aldosterone and renin concentration in the differential diagnosis of essential hypertension and primary aldosteronism. Clin Endocrinol. 57:2002;457-465
23. Jessup M., Brozena S. Heart Failure. N Engl J Med. 348:2003;2007-2018